Observational Study Evaluating the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
Phase of Trial: Phase IV
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms APPRAISE
- Sponsors Celgene Corporation
- 26 Mar 2019 Planned End Date changed from 1 Jun 2020 to 1 Sep 2020.
- 26 Mar 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Sep 2019.
- 07 Aug 2018 New trial record